Phase IV Post-Marketing Surveillance: Monitoring Safety After Regulatory Approval
Phase IV clinical studies are conducted after a medicinal product has received regulatory approval and entered the market. Unlike pre-approval trials, which are performed under controlled conditions with defined patient populations, Phase IV studies assess safety and effectiveness in broader, routine clinical practice.
Post-marketing surveillance aims to detect rare or long-term adverse effects that may not have been identified during earlier trial phases. Data sources may include observational studies, patient registries, spontaneous adverse event reporting systems, and real-world evidence analyses.
Regulatory authorities require ongoing pharmacovigilance activities to ensure continuous evaluation of a product’s benefit–risk profile. When necessary, findings from Phase IV monitoring may lead to label updates, additional warnings, usage restrictions, or further risk management measures.
For healthcare professionals, understanding post-marketing surveillance supports informed prescribing and reinforces the importance of adverse event reporting in maintaining patient safety within established regulatory frameworks.
